| Literature DB >> 36002785 |
Ahmed Shehta1, Ahmed Farouk2, Rami Said2, Ayman El Nakeeb2, Ahmed Aboelenin2, Mohamed Elshobary2, Amgad Fouad2, Ahmed Nabieh Elghawalby2.
Abstract
BACKGROUND: Bile leakage (BL) is one of the commonest morbidities after hepatic resection for hepatocellular carcinoma (HCC). The current study was conducted to evaluate the incidence and different predictive factors for BL after hepatic resection for HCC, and to evaluate of the impact of BL on the long-term survival outcomes.Entities:
Keywords: Bile leakage; Hepatic resection; Hepatocellular carcinoma; Survival
Mesh:
Year: 2022 PMID: 36002785 PMCID: PMC9568438 DOI: 10.1007/s11605-022-05433-7
Source DB: PubMed Journal: J Gastrointest Surg ISSN: 1091-255X Impact factor: 3.267
Demographic data of the study patients (TACE, transarterial chemoembolization; RFA, radiofrequency ablation)
| Variables | All cases | Non-BL group | BL group | |
|---|---|---|---|---|
| Age (years) | 60 (18–78) | 60 (18–78) | 59 (45–68) | 0.947 |
Gender Male Female | 237 (80.9%) 56 (19.1%) | 222 (80.4%) 54 (19.6%) | 15 (88.2%) 2 (11.8%) | 0.542 |
| Body mass index (kg/m2) | 28.7 (17.3–42.7) | 28.7 (17.3–42.7) | 27.9 (20.8–38.5) | 0.942 |
| Previous abdominal operations | 92 (31.4%) | 89 (32.2%) | 3 (17.6%) | 0.285 |
| Previous TACE | 18 (6.1%) | 18 (6.5%) | 0 | 0.61 |
| Previous RFA | 4 (1.4%) | 4 (1.4%) | 0 | 1 |
Complaint Accidental Pain Mass | 141 (48.1%) 150 (51.2%) 2 (0.7%) | 136 (49.3%) 138 (50%) 2 (0.7%) | 5 (29.4%) 12 (70.6%) 0 | 0.251 |
| Previous antiviral therapy | 29 (9.9%) | 28 (10.1%) | 1 (5.9%) | 1 |
| Albumin (g/dL) | 3.9 (2.1–5.3) | 3.9 (2.1–5.3) | 3.8 (2.2–4.8) | 0.85 |
| Bilirubin (mg/dL) | 0.7 (0.3–11.2) | 0.7 (0.3–2.2) | 0.7 (0.5–11.2) | 0.936 |
| Alanine aminotransferase (IU/L) | 41 (20–280) | 41 (20–280) | 35 (20–127) | 0.965 |
| Aspartate aminotransferase (IU/L) | 50 (20–240) | 50 (20–240) | 47 (20–236) | 0.942 |
| International normalized ratio | 1 (1–1.8) | 1 (1–1.8) | 1 (1–1.2) | 0.084 |
| Platelets (× 103/mL) | 145 (34–433) | 143.5 (34–433) | 159 (72–294) | 0.284 |
| Creatinine (mg/dL) | 0.8 (0.5–2.5) | 0.8 (0.5–2.5) | 0.8 (0.6–1.1) | 0.906 |
| Alpha feto-protein (ng/ml) | 30.1 (3.4–2000) | 29 (7–2000) | 195 (3.4–2000) | 0.617 |
Child–Pugh grade A B | 286 (97.6%) 7 (2.4%) | 272 (98.6%) 4 (1.4%) | 14 (82.4%) 3 (17.6%) | 0.005 |
| Model for end stage liver disease (MELD score) | 7 (6–16) | 7 (6–16) | 7 (6–16) | 0.718 |
| Hepatitis C virus | 270 (92.2%) | 254 (92%) | 16 (94.1%) | 1 |
| Hepatitis B virus | 3 (1%) | 2 (0.7%) | 1 (5.9%) | 0.165 |
Radiological and endoscopic data of the study patients
| Variables | All cases | Non-BL group | BL group | |
|---|---|---|---|---|
Liver status Cirrhosis Normal | 278 (94.9%) 15 (5.1%) | 262 (94.9%) 14 (5.1%) | 16 (94.1%) 1 (5.9%) | 0.601 |
Spleen Normal Mild splenomegaly Moderate splenomegaly Marked splenomegaly Absent | 122 (41.6%) 123 (42%) 38 (13%) 3 (1%) 7 (2.4%) | 112 (40.6%) 118 (42.8%) 36 (13%) 3 (1.1%) 7 (2.5%) | 10 (58.8%) 5 (29.4%) 2 (11.8%) 0 0 | 0.628 |
Number Single Multiple | 266 (90.8%) 27 (9.2%) | 249 (90.2%) 27 (9.8%) | 17 (100%) 0 | 0.382 |
Site Right hemi-liver Left hemi-liver Left lateral section Segment IV Right anterior section Right posterior section Central Caudate lobe Segment II Segment III Segment V Segment VI Segment VII Segment VIII Multi-site | 27 (9.2%) 14 (4.8%) 38 (13%) 12 (4.1%) 3 (1%) 14 (4.8%) 4 (1.4%) 6 (2%) 22 (7.5%) 34 (11.6%) 13 (4.4%) 45 (15.4%) 26 (8.9%) 16 (5.5%) 19 (6.5%) | 23 (8.3%) 13 (4.7%) 36 (13%) 12 (4.3%) 3 (1.1%) 12 (4.3%) 4 (1.4%) 6 (2.2%) 22 (8%) 33 (12%) 11 (4%) 45 (16.3%) 24 (8.7%) 13 (4.7%) 19 (6.9%) | 4 (23.5%) 1 (5.9%) 2 (11.8%) 0 0 2 (11.8%) 0 0 0 1 (5.9%) 2 (11.8%) 0 2 (11.8%) 3 (17.6%) 0 | 0.114 |
| Size (cm) | 6 (1.7–20) | 6 (1.7–20) | 6.3 (3–12) | 0.498 |
| Macroscopic portal vein invasion | 36 (12.3%) | 31 (11.2%) | 5 (29.4%) | 0.043 |
| Porta hepatis lymph nodes | 44 (15%) | 41 (14.9%) | 3 (17.6%) | 0.727 |
| Upper GIT endoscopy | 284 (96.9%) | 267 (96.7%) | 17 (100%) | 1 |
Endoscopy findings Esophageal veins Gastric compression | 50 (17.1%) 1 (0.3%) | 50 (18.1%) 1 (0.4%) | 0 0 | 0.144 |
Operative data of the study patients (HCC, hepatocellular carcinoma; LGL, left gastric ligation; IO RFA, intraoperative radiofrequency ablation)
| Variables | All cases | Non-BL group | BL group | |
|---|---|---|---|---|
Liver status Cirrhosis Normal | 274 (93.5%) 19 (6.5%) | 259 (93.8%) 17 (6.2%) | 15 (88.2%) 2 (11.8%) | 0.303 |
Site Right hemi-liver Left hemi-liver Caudate lobe Bilobar | 151 (51.5%) 130 (44.4%) 6 (2%) 6 (2%) | 138 (50%) 126 (45.7%) 6 (2.2%) 6 (2.2%) | 13 (76.5%) 4 (23.5%) 0 0 | 0.197 |
Lesion site details Right hemi-liver Left hemi-liver Left lateral section Segment IV Right anterior section Right posterior section Central Caudate lobe Segment II Segment III Segment V Segment VI Segment VII Segment VIII Multi-site | 24 (8.2%) 10 (3.4%) 54 (18.4%) 13 (4.4%) 2 (0.7%) 12 (4.1%) 10 (3.4%) 6 (2%) 11 (3.8%) 32 (10.9%) 13 (4.4%) 42 (14.3%) 30 (10.2%) 15 (5.1%) 19 (6.4%) | 22 (8%) 8 (2.9%) 52 (18.8%) 13 (4.7%) 1 (0.4%) 9 (3.3%) 10 (3.6%) 6 (2.2%) 11 (4%) 32 (11.6%) 11 (4%) 42 (15.2%) 27 (9.8%) 14 (5.1%) 18 (6.6%) | 2 (11.8%) 2 (11.8%) 2 (11.8%) 0 1 (5.9%) 3 (17.6%) 0 0 0 0 2 (11.8%) 0 3 (17.6%) 1 (5.9%) 1 (5.9%) | 0.008 |
Number Single Multiple | 271 (92.5%) 22 (7.5%) | 256 (92.8%) 20 (7.2%) | 15 (88.2%) 2 (11.8%) | 0.371 |
| Size (cm) | 6 (2–20) | 6 (2–20) | 6 (3–10) | 0.523 |
| Vascular invasion | 39 (13.3%) | 34 (12.3%) | 5 (29.4%) | 0.049 |
| Biliary invasion | 1 (0.3%) | 0 | 1 (5.9%) | 0.058 |
| Nearby organ invasion | 19 (6.5%) | 18 (6.5%) | 1 (5.9%) | 1 |
| Lymph nodes | 25 (8.5%) | 22 (8%) | 3 (17.6%) | 0.168 |
Lymph nodes site Porta-hepatis Supra-duodenal | 22 (7.5%) 2 (0.7%) | 19 (6.9%) 2 (0.7%) | 3 (17.6%) 0 | 1 |
| Intraoperative biopsies | 16 (5.5%) | 14 (5.1%) | 2 (11.8%) | 0.235 |
Biopsy site Suspicious liver nodule Safety margin Lymph nodes | 3 (1%) 5 (1.7%) 8 (.7%) | 3 (1.1%) 5 (1.8%) 6 (2.2%) | 0 0 2 (11.8%) | 0.515 |
Biopsy result HCC High-grade tumor Negative | 5 (1.7%) 1 (0.3%) 10 (3.4%) | 5 (1.8%) 1 (0.4%) 8 (.9%) | 0 0 2 (11.8%) | 0.504 |
Surgery approach Open Laparoscopic Failed laparoscopic | 287 (98%) 4 (1.4%) 2 (0.7%) | 270 (97.8%) 4 (1.4%) 2 (0.7%) | 17 (100%) 0 0 | 0.828 |
Liver resection extent Minor Major | 224 (76.5%) 69 (23.5%) | 219 (79.3%) 57 (20.7%) | 5 (29.4%) 12 (70.6%) | 0.001 |
Liver resection type Tumorectomy Segmentectomy Left lateral sectionectomy Right anterior sectionectomy Right posterior sectionectomy Left hepatectomy Extended left hepatectomy Right hepatectomy Extended right hepatectomy Central hepatectomy Caudate lobectomy Multiple resections | 139 (47.4%) 6 (2%) 66 (22.5%) 1 (0.3%) 1 (0.3%) 13 (4.4%) 1 (0.3%) 50 (17.1%) 5 (1.7%) 1 (0.3%) 6 (2%) 4 (1.4%) | 137 (49.6%) 5 (1.8%) 64 (23.2%) 1 (0.4%) 1 (0.4%) 11 (4%) 1 (0.4%) 41 (14.9%) 4 (1.4%) 1 (0.4%) 6 (2.2%) 4 (1.4%) | 2 (11.8%) 1 (5.9%) 2 (11.8%) 0 0 2 (11.8%) 0 9 (52.9%) 1 (5.9%) 0 0 0 | 0.008 |
| Associated portal thrombectomy | 6 (1.4%) | 5 (1.8%) | 1 (5.9%) | 0.304 |
| Associated extrahepatic biliary resection | 1 (0.3%) | 0 | 1 (5.9%) | 0.058 |
| Pringle procedure use | 44 (15%) | 37 (13.4%) | 7 (41.2%) | 0.007 |
Pringle indication Elective Emergency | 27 (9.2%) 17 (5.8%) | 23 (8.3%) 14 (5.1%) | 4 (23.5%) 3 (17.6%) | 1 |
| Pringle duration (minutes) | 17.5 (10–90) | 20 (10–90) | 15 (10–30) | 1 |
| Operation time (hours) | 3 (1.2–7) | 3 (1.2–6) | 4 (3–7) | 0.001 |
| Blood loss (ml) | 600 (50–6000) | 600 (50–6000) | 1300 (200–4000) | 0.012 |
| Blood transfusion | 144 (49.1%) | 132 (47.8%) | 12 (70.6%) | 0.082 |
| Associated operation | 82 (28%) | 79 (28.6%) | 3 (17.6%) | 0.414 |
Postoperative data of the study patients (ICU, intensive care unit; PHLF, post-hepatectomy liver failure; US, ultrasound; ERCP, endoscopic retrograde cholangio-pancreatography)
| Variables | All cases | Non-BL group | BL group | |
|---|---|---|---|---|
| ICU duration (days) | 1 (1–22) | 1 (1–22) | 1 (1–2) | 0.972 |
| Hospital stay (days) | 5 (2–66) | 5 (2–31) | 15 (7–66) | 0.001 |
| Morbidity | 153 (52.2%) | 136 (49.3%) | 17 (100%) | 0.001 |
Clavien-Dindo grade I II III-a III-b IV-a V | 64 (21.8%) 47 (16%) 12 (4.1%) 10 (3.4%) 2 (0.7%) 18 (6.1%) | 61 (22.1%) 45 (16.3%) 8 (2.9%) 5 (1.8%) 0 17 (6.2%) | 3 (17.6%) 2 (11.8%) 4 (23.5%) 5 (29.4%) 2 (11.8%) 1 (5.9%) | 0.001 |
Morbidity type General Surgical Liver-related Mixed | 4 (1.4%) 7 (2.4%) 108 (36.9%) 34 (11.6%) | 4 (1.4%) 6 (2.2%) 100 (36.2%) 26 (9.4%) | 0 1 (5.9%) 8 (47.1%) 8 (47.1%) | 0.061 |
| PHLF | 138 (47.1%) | 127 (46%) | 11 (64.7%) | 0.143 |
PHLF grade A B C | 77 (26.3%) 41 (14%) 20 (6.8%) | 75 (27.2%) 35 (12.7%) 17 (6.2%) | 2 (11.8%) 6 (35.3%) 3 (17.6%) | 0.032 |
| Bile leakage | 17 (5.8%) | 0 | 17 (100%) | –- |
Bile leakage treatment Conservative US-guided tube ERCP Operative | 6 (2%) 3 (1%) 7 (2.4%) 1 (0.3%) | 0 | 6 (35.3%) 3 (17.6%) 7 (41.2%) 1 (5.9%) | –- |
| Collection | 14 (4.8%) | 11 (4%) | 3 (17.6%) | 0.04 |
Collection treatment Conservative US-guided tube Operative | 6 (2%) 7 (2.4%) 1 (0.3%) | 6 (2.2%) 5 (1.8%) 0 | 0 2 (11.8%) 1 (5.9%) | 0.063 |
Internal hemorrhage Managed surgically | 6 (2%) | 6 (2.2%) | 0 | 1 |
Wound infection All bed side management | 9 (3.1%) | 7 (2.5%) | 2 (11.8%) | 0.09 |
Liver abscess All US-guided drainage | 3 (1%) | 2 (0.7%) | 1 (5.9%) | 0.165 |
Vascular complications All PVT | 5 (1.7%) | 5 (1.8%) | 0 | 1 |
Respiratory complications Pleural effusion Pneumonia | 17 (5.8%) 16 (5.5%) 1 (0.3%) | 14 (5.1%) 13 (4.7%) 1 (0.4%) | 3 (17.6%) 3 (17.6%) 0 | 0.066 |
Respiratory treatment Conservative US-guided drainage | 13 (4.4%) 4 (1.4%) | 11 (4%) 3 (1.1%) | 2 (11.8%) 1 (5.9%) | 1 |
| Cardiac dysrhythmia | 1 (0.3%) | 1 (0.4%) | 0 | 1 |
Renal complications All hepato-renal syndrome | 4 (1.4%) | 4 (1.4%) | 0 | 1 |
| Cerebral stroke | 1 (0.3%) | 1 (0.4%) | 0 | 1 |
| Ileus | 1 (0.3%) | 1 (0.4%) | 0 | 1 |
Bleeding varices Endoscopic management | 1 (0.3%) | 1 (0.4%) | 0 | 1 |
| Early mortality | 20 (6.8%) | 19 (6.9%) | 1 (5.9%) | 1 |
Early mortality cause Liver failure | 20 (6.8%) | 19 (6.9%) | 1 (5.9%) | 1 |
Pathological data of the study patients
| Variables | All cases | Non-BL group | BL group | |
|---|---|---|---|---|
| Size (cm) | 6 (1.5–20) | 6 (1.5–20) | 5.5 (2.5–16) | 0.96 |
Number Single Multiple | 254 (86.7%) 39 (13.3%) | 238 (86.2%) 38 (13.8%) | 16 (94.1%) 1 (5.9%) | 0.71 |
Resection margin R0 R1 | 259 (88.4%) 34 (11.6%) | 244 (88.4%) 32 (11.6%) | 15 (88.2%) 2 (11.8%) | 1 |
| Capsular invasion | 109 (37.2%) | 103 (37.3%) | 6 (35.3%) | 1 |
| Microvascular invasion | 140 (47.8%) | 131 (47.5%) | 9 (52.9%) | 0.804 |
| Perineural invasion | 119 (40.6%) | 111 (40.2%) | 8 (47.1%) | 0.617 |
Tumor grade I II III IV No viable tumor | 55 (18.8%) 170 (58%) 59 (20.1%) 8 (2.7%) 1 (0.3%) | 51 (18.5%) 163 (59.1%) 55 (19.9%) 6 (2.2%) 1 (0.4%) | 4 (23.5%) 7 (41.2%) 4 (23.5%) 2 (11.8%) 0 | 0.155 |
Tumor stage T1 T2 T3 T4 Tx | 75 (25.6%) 174 (59.4%) 39 (13.3%) 4 (1.4%) 1 (0.3%) | 73 (26.4%) 163 (59.1%) 36 (13%) 3 (1.1%) 1 (0.4%) | 2 (11.8%) 11 (64.7%) 3 (17.6%) 1 (5.9%) 0 | 0.349 |
Liver background Cirrhosis Normal | 276 (94.2%) 17 (5.8%) | 259 (93.8%) 17 (6.2%) | 17 (100%) 0 | 0.609 |
Fig. 1A Kaplan–Meier overall survival curve of all study cases. B Kaplan–Meier disease-free survival curve of all study cases
Fig. 2A Kaplan–Meier overall survival curve of both groups (log-rank; chi square 0.105–df: 1–p = 0.746). B Kaplan–Meier disease-free survival curve of both groups (log-rank; chi square 0.881–df: 1–p = 0.348)
Recurrence and survival data of the study patients
| Variables | All cases | Non-BL group | BL group | |
|---|---|---|---|---|
| Mortality | 89 (30.4%) | 85 (30.8%) | 4 (23.5%) | 0.598 |
| Survival time (month) | 17 (4–110) | 17 (4–110) | 12 (4–42) | 0.167 |
Overall survival 1 year 3 years 5 years | 85.9% 68.9% 49.5% | 86.2% 67.8% 49.3% | 79.6% 70.8% 70.8% | Log-rank 0.746 |
| Recurrence | 133 (45.4%) | 129 (46.7%) | 4 (23.5%) | 0.044 |
| Recurrence time (month) | 14 (1–110) | 14 (1–110) | 12 (1–40) | 0.204 |
Disease-free survival 1 year 3 years 5 years | 74.3% 42.8% 26.7% | 73.2% 42.2% 26.2% | 84.4% 50.6% 50.6% | Log-rank 0.348 |
Recurrence site Intrahepatic Extrahepatic Both | 101 (34.5%) 5 (1.7%) 27 (9.2%) | 100 (36.2%) 4 (1.4%) 25 (9.1%) | 1 (5.9%) 1 (5.9%) 2 (11.8%) | 0.017 |
Intrahepatic site Liver margin Same liver lobe Other liver lobe Bilobar | 4 (1.4%) 30 (10.2%) 41 (14%) 53 (18.1%) | 4 (1.4%) 29 (10.5%) 39 (14.1%) 53 (19.2%) | 0 1 (5.9%) 2 (11.8%) 0 | 0.449 |
Intrahepatic treatment Resection TACE RFA MWA Combined therapy Systemic therapy Supportive | 2 (0.7%) 37 (12.6%) 9 (3.1%) 7 (2.4%) 12 (4.1%) 1 (0.3%) 60 (20.5%) | 2 (0.7%) 37 (13.4%) 9 (3.3%) 7 (2.5%) 12 (4.3%) 1 (0.4%) 57 (20.7%) | 0 0 0 0 0 0 3 (17.6%) | 0.968 |
Extrahepatic site Lung Bone Brain Peritoneum Adrenal gland Abdominal wall Lymph nodes Multi-site | 12 (4.1%) 5 (1.7%) 1 (0.3%) 5 (1.7%) 1 (0.3%) 1 (0.3%) 2 (0.7%) 5 (1.7%) | 10 (3.6%) 5 (1.8%) 1 (0.4%) 5 (1.8%) 1 (0.4%) 0 2 (0.7%) 2 (0.7%) | 2 (11.8%) 0 0 0 0 1 (5.9%) 0 0 | 0.135 |
Predictive factors of biliary leakage (TACE, transarterial chemoembolization; RFA, radiofrequency ablation; MELD, model for end stage liver disease)
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | 1.001 (0.001–0.031) | 0.984 | ||
| Gender | 0.601 (0.601–0.768) | 0.434 | ||
| Previous TACE | 18.48 (18.29–94.605) | 0.998 | ||
| Previous RFA | 18.43 (0.25–122.996) | 0.999 | ||
| Albumin | 0.067 (0.518–0.016) | 0.898 | ||
| Bilirubin | 0.456 (0.261–3.051) | 0.081 | ||
| Alanine aminotransferase | 0.001 (0.007–0.013) | 0.909 | ||
| Aspartate aminotransferase | 0.005 (0.006–0.723) | 0.935 | ||
| International normalized ratio | 6.264 (3.608–3.014) | 0.083 | ||
| Platelets | 0.003 (0.003–0.848) | 0.357 | ||
| Creatinine | 0.453 (0.991–0.209) | 0.647 | ||
| Alpha feto-protein | 0 (0–1.847) | 0.174 | ||
| Child–Pugh grade | 2.679 (0.142–0.764) | 0.001 | 2.502 (0.762–0.906) | 0.006 |
| MELD score | 0.022 (0.148–1.124) | 0.88 | ||
| Hepatitis C virus | 0.326 (0.096–1.054) | 0.757 | ||
| Hepatitis B virus | 2.147 (1.251–2.944) | 0.086 | ||
| Tumor Site | 1.131 (0.566–0.75) | 0.046 | 0.174 (0.593–0.086) | 0.769 |
| Portal vein invasion | 1.19 (0.296–0.565) | 0.035 | 0.404 (0.667–0.3.67) | 0.545 |
| Biliary invasion | 24.051 (4.254–45.559) | 1 | ||
| Liver resection extent (minor vs major) | 1.558 (0.318–0.553) | 0.001 | 1.813 (0.295–0.788) | 0.021 |
| Pringle procedure | 1.509 (0.524–0.885) | 0.004 | 1.592 (0.625–1.045) | 0.011 |
| Operation time | 0.818 (0.208–0.883) | 0.001 | 0.301 (0.295–4.75) | 0.307 |
| Blood loss | 3.168 (0.359–3.032) | 0.082 | ||
| Blood transfusion | 0.962 (0.546–3.11) | 0.078 | ||
| Morbidity | 19.123 (3.925–339.276) | 0.996 | ||
| Morbidity grade | 0.221 (0.114–3.774) | 0.052 | ||
| Pathologic variant | 1.385 (1.94–14.99) | 0.999 | ||
| Tumor size | 0.031 (0.07–1.947) | 0.66 | ||
| Number (single/multiple) | 0.938 (0.805–1.045) | 0.37 | ||
| Resection margin (R0/R1) | 0.017 (0.776–9.667) | 0.983 | ||
| Capsular invasion | 0.88 (0.523–10.706) | 0.867 | ||
| Microvascular invasion | 0.219 (0.501–9.961) | 0.661 | ||
| Perineural invasion | 0.279 (0.501–8.465) | 0.578 | ||
| Tumor grade | 0.303 (0.329–3.438) | 0.358 | ||
| Tumor stage | 0.537 (0.332–2.619) | 0.106 | ||
| Liver background (cirrhosis/normal) | 18.479 (19.496–39.682) | 1 | ||